[Edaily Reporter KIM SUNG-JIN ] Celltrion(068270)has significantly revised its development strategy for a biosimilar of the global blockbuster anticancer drug “Dazalex.” The company has redesigned the strategy to focus on pharmacokinetic equivalence, excluding “therapeutic equivalence”—which measures the drug’s efficacy—from the primary endpoints. Celltrion logo. (Photo courtesy of Celltrion) Celltrion’s revision of its clinical strategy is interpreted as a move to reduce the clinical burden and shorten the timeline. This decision appears to align with the trend toward streamlining comparative efficacy trials for biosimilars in global markets such as the U.S. and Europe.
Pharmacokinetics as the Sole Primary Endpoint… Original Drug Administration Period Halved
According to the pharmaceutical and biotech industry on the 28th, Celltrion Pharm Inc. has revised the design of its global Phase 3 clinical trial for “CT-P44,” a biosimilar of the multiple myeloma treatment Darzalex. Data from the U.S. clinical trial registry ClinicalTrials.gov and the European Union (EU) Clinical Trials Information System (CTIS) indicate that the primary endpoint has been changed.
Darzalex, the drug CT-P44 is targeting, is a major anticancer drug that generates over $10 billion in annual sales in the global market. It is a monoclonal antibody containing daratumumab and is used to treat patients with multiple myeloma. Celltrion is developing a biosimilar of Darzalex PassPro, the subcutaneous injection formulation.
The most notable change is the removal of “therapeutic equivalence” from the list of primary endpoints. In the original clinical trial, two key objectives were set: pharmacokinetic (PK) equivalence and therapeutic equivalence; however, in the revised design, only pharmacokinetic equivalence remains as a primary endpoint.
In the original design, pharmacokinetic equivalence was to be verified by comparing the plasma drug exposure levels of CT-P44 and Dazalex after administration, while therapeutic equivalence was to be assessed based on the proportion of patients achieving a Very Good Partial Response (VGPR) or better up to 24 weeks after dosing.
Endpoints related to therapeutic efficacy have been reclassified as secondary endpoints. Overall response rate (ORR), minimal residual disease (MRD) negativity rate, progression-free survival (PFS), and overall survival (OS) have also been included as secondary endpoints. This is interpreted as effectively prioritizing the demonstration of plasma drug exposure over therapeutic efficacy.
An official from the biosimilar industry stated, “As the hurdles for biosimilar development are lowering, the scale and timelines of development are being scaled back in various ways; this revision to the evaluation criteria also appears to be part of this trend.”
Another noteworthy change is the alteration in the dosing regimen compared to the originator drug. According to U.S. clinical data, while Dalalex was previously administered for up to 13 cycles, the revised clinical trial has shortened this to a maximum of 6 cycles. Considering that one cycle is 28 days, this effectively reduces the maximum treatment duration for the originator drug from approximately 52 weeks to 24 weeks. Starting from the 7th cycle, patients in the control group who had been receiving the originator drug will switch to CT-P44, while patients who started with CT-P44 from the beginning will continue their treatment.
FDA and EMA Push to Streamline Comparative Efficacy Trials… Development Costs Expected to Decrease
Celltrion’s revision of its clinical strategy is drawing attention as it aligns with moves by regulatory authorities in the U.S. and Europe to ease regulations on biosimilar development.
Last October, the U.S. Food and Drug Administration (FDA) released draft guidelines reevaluating the necessity of comparative efficacy trials for biosimilars. The guidelines essentially state that if functional similarity and pharmacokinetic equivalence between a biosimilar and the originator drug are established, a separate large-scale comparative efficacy trial may not be required.
According to the FDA’s announcement at the time, equivalence studies typically take 1 to 3 years and cost an average of $24 million (approximately 32.1 billion won). Since biosimilars are not new drugs, the intent is to streamline the development process—eliminating the need for such significant investment of time and money—provided that structural equivalence with the existing originator drug is established.
This trend is also emerging in Europe. The European Medicines Agency (EMA) also pushed for the streamlining of clinical trials in biosimilar development this past March. Similarly, the key point is that separate comparative efficacy trials may not be required if the biosimilar is structurally similar to the originator drug and pharmacokinetic data are available.
Another biosimilar industry official stated, “It appears that the clinical trial design was modified following prior consultation with regulatory authorities in line with the trend toward deregulation in biosimilar development.”
As Development Barriers Lower, Competition to Expand Pipelines Heats Up
Already, within the domestic biosimilar industry, there have been a series of cases where companies are scaling back clinical trial sizes or omitting large-scale comparative efficacy trials in line with global regulatory easing. Taking Celltrion’s CT-P44, currently under development, as an example, the company took steps last July to significantly reduce the target number of patients for its global Phase 3 clinical trial, thereby cutting development schedules and costs across the board. The company received approval in Korea and Europe for a protocol amendment reducing the Phase 3 target patient enrollment from 486 to 394—a decrease of 92 patients (approximately 19%) compared to the original plan. In addition, the projected date for completion of the primary evaluation was moved up from November 2027 to March 2027.
Furthermore, Celltrion reduced the target patient enrollment for the global Phase 3 clinical trial of its Keytruda biosimilar, CT-P51, from 606 to 220, and for its Cosentyx biosimilar, CT-P55, from 375 to 153. Aprogen also announced that, following a meeting with the FDA last May, it secured a determination that its Herceptin biosimilar, AP063, could proceed with development based on analytical data, clinical pharmacokinetics (PK), and immunogenicity assessments—without the need for a Phase 3 clinical trial.
As major countries lower the barriers to biosimilar development, the market is expected to change rapidly in the future. A prime example is India’s Biocon Biologics. Biocon has unveiled a roadmap to launch a cumulative total of 20 biosimilars by 2030. The company explained that the FDA’s relaxation of clinical regulations is expected to reduce the development costs of complex biosimilars by about 50 percent, adding that lower development costs will enable the company to develop more products and bring them to market more quickly.
Sandoz, a global biosimilar company based in Switzerland, also announced its “Bio100” strategy last September, stating its intention to expand its current biosimilar portfolio—which currently stands at 13 products—to more than 100 by 2040. To achieve this, the company plans to invest approximately $300 million in Slovenia to build additional production facilities for biosimilar active pharmaceutical ingredients (APIs).
In South Korea, Samsung Bioepis announced in January its goal to expand its biosimilar portfolio to 20 products by 2030, while Celltrion set a target in March of this year to commercialize 18 biosimilars by 2030 and 41 by 2038.
SamsungElectronics will maintain a dual-leadership structure with Jeon Young-hyun, head of the Semiconductor (DS) Division, and Roh Tae-moon, head of the Device Experience (DX) Division. However, the …
NamyangDairyProducts has joined actress Nam Bo-ra in a joint donation by supplementing the supply of infant formula she had purchased out of her own pocket for single-mother families. The connection f…
ROBOTIS(108490)will supply robot actuators worth approximately 4 billion won to French robotics developer Polen Robotics. This contract covers the first batch, and additional orders are expected in th…